(45) retrospectively analyzed 18F-FDG PET/CT data from 173 NSCLC patients (71 EGFR+, 102 EGFR−), with 39% (68/173) at stages I/II and 61% (105/173) at stages III/IV. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.